Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Tumor-Treating Fields

Tumor-Treating Fields Research Original Investigation Treatment With Tumor-Treating Fields in Patients With Glioblastoma 28. Vordermark D. Avoiding bias in the prospective and interpretation of serial quality of life iii study of bevacizumab, temozolomide, and evaluation of patients with brain metastases. J Clin assessments in patients with malignant glioma. radiotherapy in newly diagnosed glioblastoma. Oncol. 2007;25(25):4023. J Neurooncol. 2003;63(2):179-186. J Clin Oncol. 2015;33(19):2166-2175. 29. Walker M, Brown J, Brown K, Gregor A, Whittle 30. Taphoorn MJ, Henriksson R, Bottomley A, et al. IR, Grant R. Practical problems with the collection Health-related quality of life in a randomized phase Invited Commentary Answering the Concern About Quality of Life Lia M. Halasz, MD; Timur Mitin, MD, PhD Since the 2005 publication of the randomized European these data, published by Taphoorn and colleagues in this Organization for Research and Treatment of Cancer/National issue of JAMA Oncology, presents important data for evaluat- Cancer Institute of Cancer trial that established concurrent ing the overall effect of TTFields on our patients. In contrast radiotherapy (RT) and temo- to the interim report, the investigators found no significant dif- zolomide for upfront treat- ference in HRQoL between the 2 treatment arms, except for ment of glioblastoma (GBM), itchy skin, which http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Oncology American Medical Association

Tumor-Treating Fields

Halasz, Lia M.; Mitin, Timur
JAMA Oncology , Volume 4 (4) – Apr 1, 2018
Download PDF
2 pages

Loading next page...
 
/lp/american-medical-association/tumor-treating-fields-p0hif3g3Ep

References (11)

Publisher
American Medical Association
Copyright
Copyright 2018 American Medical Association. All Rights Reserved.
ISSN
2374-2437
eISSN
2374-2445
DOI
10.1001/jamaoncol.2017.5062
Publisher site
See Article on Publisher Site

Abstract

Research Original Investigation Treatment With Tumor-Treating Fields in Patients With Glioblastoma 28. Vordermark D. Avoiding bias in the prospective and interpretation of serial quality of life iii study of bevacizumab, temozolomide, and evaluation of patients with brain metastases. J Clin assessments in patients with malignant glioma. radiotherapy in newly diagnosed glioblastoma. Oncol. 2007;25(25):4023. J Neurooncol. 2003;63(2):179-186. J Clin Oncol. 2015;33(19):2166-2175. 29. Walker M, Brown J, Brown K, Gregor A, Whittle 30. Taphoorn MJ, Henriksson R, Bottomley A, et al. IR, Grant R. Practical problems with the collection Health-related quality of life in a randomized phase Invited Commentary Answering the Concern About Quality of Life Lia M. Halasz, MD; Timur Mitin, MD, PhD Since the 2005 publication of the randomized European these data, published by Taphoorn and colleagues in this Organization for Research and Treatment of Cancer/National issue of JAMA Oncology, presents important data for evaluat- Cancer Institute of Cancer trial that established concurrent ing the overall effect of TTFields on our patients. In contrast radiotherapy (RT) and temo- to the interim report, the investigators found no significant dif- zolomide for upfront treat- ference in HRQoL between the 2 treatment arms, except for ment of glioblastoma (GBM), itchy skin, which

Journal

JAMA Oncology – American Medical Association

Published: Apr 1, 2018

There are no references for this article.